Long-term Experience With Abatacept SC in Routine Clinical Practice

Trial Profile

Long-term Experience With Abatacept SC in Routine Clinical Practice

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASCORE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 19 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Jun 2016 Planned number of patients changed from 3046 to 2896.
    • 12 Apr 2016 Planned number of patients changed from 2216 to 3046.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top